A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Phase 2: Objective response (OR) based on Blinded independent central review (BICR) assessment per RECIST version 1.1, Phase 3: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.

Phase 2: PFS based on BICR assessment per RECIST version 1.1., Phase 2: Duration of response (DoR) based on BICR assessment per RECIST version 1.1., Phase 2: Disease control rate (DC) based on BICR assessment per RECIST version 1.1., Phase 2: Overall Survival, Phase 3: Overall Survival, Phase 3: OR based on BICR assessment per RECIST version 1.1., Phase 3: DoR based on BICR assessment per RECIST version 1.1., Phase 3: DC based on BICR assessment per RECIST version 1.1., Phase 3: Change from baseline at Week 12 in physical functioning as measured by the EORTC QLQ‑C30, Phase 3: Change from baseline at Week 12 in key lung cancer symptoms as measured by the EORTC QLQ-LC13., Phase 3: Change from baseline at Week 12 in GHS/QoL as measured by the EORTC QLQ-C30.

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Italy, Portugal, Spain